BOSTON and SOUTH SAN FRANCISCO, Calif. — Frontier Medicines Corporation, a precision medicine company seeking to unlock the proteome to advance breakthrough therapies against otherwise undruggable disease-causing targets, today announced that Chris Varma, Ph.D., Frontier’s co-founder, chairman, and CEO, will participate in a fireside chat at the Credit Suisse 31^st Annual Healthcare Conference at 9:10 a.m. PT on November 8, 2022 in Rancho Palos Verdes, CA.

A live audio webcast of the event will be available for access in the News & Media section of Frontier’s website (LINK). An archived replay will be accessible for 30 days following the event.

About Frontier Medicines

Frontier Medicines is a precision medicine company that has pioneered a powerful discovery and development platform designed to generate medicines against disease-causing proteins previously considered undruggable. The company is deploying its technologies in chemoproteomics, covalent drug discovery, and machine learning to potentially develop groundbreaking medicines for genetically-defined patient populations, starting in cancer. Frontier is advancing its wholly-owned pipeline of precision medicines against the most important drivers of cancer. The company’s lead program is focused on KRAS^G12C and is distinct in that it targets direct inhibition of both the activated and inactive forms of KRAS^G12C. This KRAS mutation is found most prevalently in patients with non-small cell lung, colorectal, and pancreatic cancers. For more information on how Frontier is boldly advancing science to defeat disease, visit www.frontiermeds.com and follow us on LinkedIn and Twitter.